Key Points
- William Guyer sold 20,000 CORT shares at an average price of $40.97 under a pre‑arranged Rule 10b5‑1 plan, raising about $819,400 and cutting his stake by roughly 90% to ~2,231 shares.
- Corcept missed the quarter: $0.20 EPS vs. $0.33 expected and $202.13M revenue vs. $254.94M expected; the stock trades in a 12‑month range of $28.66–$91.00 and has a market cap of about $4.45B.
- Multiple securities class‑action filings and plaintiff solicitations allege misstatements tied to FDA data, increasing litigation risk and headline pressure with an April 21, 2026 lead‑plaintiff deadline.
Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider William Guyer sold 20,000 shares of the company's stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $40.97, for a total value of $819,400.00. Following the sale, the insider owned 2,231 shares of the company's stock, valued at approximately $91,404.07. This represents a 89.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
William Guyer also recently made the following trade(s):
- On Friday, March 20th, William Guyer sold 11,767 shares of Corcept Therapeutics stock. The shares were sold at an average price of $36.01, for a total value of $423,729.67.
- On Wednesday, March 4th, William Guyer sold 8,233 shares of Corcept Therapeutics stock. The shares were sold at an average price of $35.99, for a total value of $296,305.67.
- On Tuesday, February 3rd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $40.87, for a total value of $817,400.00.
Corcept Therapeutics Stock Performance
Shares of CORT opened at $41.87 on Thursday. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $91.00. The stock has a fifty day moving average price of $37.54 and a 200-day moving average price of $58.83. The company has a current ratio of 2.92, a quick ratio of 2.85 and a debt-to-equity ratio of 0.01. The firm has a market cap of $4.45 billion, a PE ratio of 51.06 and a beta of 0.25.
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The business had revenue of $202.13 million for the quarter, compared to analysts' expectations of $254.94 million. During the same quarter in the prior year, the company posted $0.26 EPS. The business's revenue for the quarter was up 11.1% on a year-over-year basis. Equities research analysts predict that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.
Trending Headlines about Corcept Therapeutics
Here are the key news stories impacting Corcept Therapeutics this week:
- Negative Sentiment: Multiple securities class-action filings and firm solicitations allege misstatements related to FDA data concerns and investor losses, and several firms are reminding shareholders of an April 21, 2026 lead‑plaintiff deadline. This amplifies potential litigation risk and headline pressure on CORT. Corcept (CORT) Class Action Alleges Misstatements on FDA Data Concerns - Hagens Berman
- Negative Sentiment: Numerous plaintiff firms (Rosen, Kahn Swick & Foti, Pomerantz, Bronstein Gewirtz & Grossman, Kaplan Fox, Rosen, Gross, others) are actively soliciting Corcept investors and urging lead‑plaintiff filings for the same class period — increasing the likelihood of consolidated litigation and associated distraction/costs. ROSEN deadline alert
- Negative Sentiment: Insider sale: director William Guyer sold 20,000 shares at ~$40.97 under a pre‑arranged Rule 10b5‑1 plan (proceeds ~$819K), leaving him with ~2,231 shares — an ~90% decline in his holding. Large insider sales can be viewed negatively even if pre‑planned. SEC filing: Guyer sale
Institutional Investors Weigh In On Corcept Therapeutics
A number of institutional investors have recently modified their holdings of CORT. Abacus FCF Advisors LLC acquired a new stake in Corcept Therapeutics in the 3rd quarter worth about $3,238,000. JPMorgan Chase & Co. lifted its stake in Corcept Therapeutics by 223.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company's stock worth $70,632,000 after purchasing an additional 587,053 shares in the last quarter. Pacer Advisors Inc. lifted its stake in Corcept Therapeutics by 6,796.7% in the 3rd quarter. Pacer Advisors Inc. now owns 390,559 shares of the biotechnology company's stock worth $32,459,000 after purchasing an additional 384,896 shares in the last quarter. Brown Capital Management LLC purchased a new position in Corcept Therapeutics in the 3rd quarter worth approximately $19,950,000. Finally, Synergy Asset Management LLC lifted its stake in Corcept Therapeutics by 96.1% in the 3rd quarter. Synergy Asset Management LLC now owns 506,856 shares of the biotechnology company's stock worth $39,615,000 after purchasing an additional 248,362 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities analysts recently issued reports on CORT shares. HC Wainwright cut their target price on Corcept Therapeutics from $67.00 to $60.00 and set a "buy" rating on the stock in a research report on Wednesday, March 25th. Canaccord Genuity Group upped their target price on Corcept Therapeutics from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, March 26th. UBS Group started coverage on Corcept Therapeutics in a research report on Tuesday, December 16th. They issued a "neutral" rating and a $95.00 target price on the stock. Weiss Ratings reissued a "hold (c)" rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Finally, Truist Financial raised Corcept Therapeutics to a "strong-buy" rating in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $77.67.
View Our Latest Stock Report on CORT
About Corcept Therapeutics
(
Get Free Report)
Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.
The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
